



# GLAND PHARMA LIMITED

January 11, 2024

BSE Limited  
Corporate Relationship Department  
Phiroze Jeejeebhoy Towers  
25<sup>th</sup> floor, Dalal Street  
Mumbai - 400 001  
Scrip Code: 543245

National Stock Exchange of India Limited  
Listing Department  
Exchange Plaza, 5th floor  
Plot no. C-1, Block G, Bandra Kurla Complex Bandra  
(East), Mumbai - 400 051  
Symbol: GLAND (ISIN: INE068V01023)

Dear Sir/Madam,

**Sub: Intimation of Board Meeting under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

This is to inform you that a meeting of the Board of Directors of Gland Pharma Limited ('the Company') will be held on **Wednesday, 14<sup>th</sup> February, 2024** *inter alia*, to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2023.

**Trading Window:**

In continuation to our earlier intimation dated December 29, 2023; this is to inform you that the trading window, which was closed from **Monday, 01<sup>st</sup> January 2024** in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended; will reopen on **Saturday, 17<sup>th</sup> February, 2024**.

**Earnings Call:**

The Investor/Analyst call will be held on Wednesday, 14<sup>th</sup> February, 2024 at 18:30 Hrs (IST). Further details will be intimated to the stock exchanges and published on the Company's website ([www.glandpharma.com](http://www.glandpharma.com)) in due course.

This is for your information and records.

**Yours truly,  
For Gland Pharma Limited**

**Sampath Kumar Pallerlamudi  
Company Secretary and Compliance Officer**